Tracy Ashby
Pulmonary Disease · Jacksonville, FLNPI 1881950210
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (50.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 68.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $3,747 and has fallen 74.3% since, to $965 in 2025.
Across 35 payments — averaging $170.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Merit Medical Systems Inc$744
- Regeneron Healthcare Solutions, Inc.$168
- Johnson & Johnson$141
- Pulmonx Corporation$129
- AstraZeneca$122
- plus $552 from 9 others
Across 6 payments — averaging $17,699 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$64K
- Roche Products Limited$42K
What the payments were for
- Travel & lodging$93016%
- Food & beverage$2,02334%
- Education$3,00050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $4,097 |
| Merit Medical Systems Inc | 7 | $744 |
| Regeneron Healthcare Solutions, Inc. | 3 | $168 |
| Johnson & Johnson | 1 | $141 |
| Pulmonx Corporation | 1 | $129 |
| AstraZeneca | 1 | $122 |
| Insmed, Inc. | 1 | $116 |
| GSK | 5 | $115 |
| Genentech, Inc. | 2 | $101 |
| Grifols Shared Services North America, Inc. | 1 | $97 |
| Boehringer Ingelheim | 1 | $30 |
| Sanofi | 1 | $27 |
| Inogen, Inc. | 1 | $26 |
| United Therapeutics Corporation | 1 | $24 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,984
- AERO Stent & del system$350
- AEROMini Fully Covered Tracheobronchial Stent$339
- MONARCH$141
- CHARTIS CATHETER$129
- ZEPHYR DELIVERY CATHETER$129
- ZEPHYR ENDOBRONCHIAL VALVE$129
- PULMONX CHARTIS TABLET CONSOLE$129
- TAGRISSO$122
- Arikayce$116
- DUPIXENT$104
How this compares
$5,954 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $160,756 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $112,391 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $22,148 |
| Incruse ElliptaUmeclidinium Bromide | 35 | $14,829 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $11,996 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,719 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $9,714 |
| Spiriva HandihalerTiotropium Bromide | 19 | $9,599 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $8,874 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 174 | $6,581 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,830 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $5,752 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $4,857 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $2,962 |
| Varenicline Tartrate | 11 | $2,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $115 | $160,086221 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere | $122 | $25,72769 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $30 | $15,54525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Jacksonville
- Jennifer FultonJacksonville$665K
- Jose Soto SotoJacksonville$504K
- Jorge MalleaJacksonville$457K
- Abubakr BajwaJacksonville$414K
- Bryan HustaJacksonville$283K
- Sebastian Fernandez-BussyJacksonville$257K
- Peter NassarJacksonville$141K
- Charles BurgerJacksonville$124K
- Daniel WyzanJacksonville$100K
- David Abia TrujilloJacksonville$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.